Observational studyMedicine2018
Serum osteoinductive factor is associated with microalbuminuria and diabetic nephropathy in type 2 diabetes.
Observational study in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Exploring the role of osteoglycin in type 2 diabetes: implications for insulin resistance and vascular pathophysiology.American journal of physiology. Endocrinology and metabolism · 2023Article
- Osteoglycin as a Potential Biomarker of Mild Kidney Function Impairment in Type 2 Diabetes Patients.Journal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the relationship between serum osteoinductive factor (OIF) and diabetic nephropathy (DN), and its potential use as a diagnostic marker for DN.This study included 177 patients with type 2 diabetes mellitus (T2DM) with normoalbuminuria, 42 with DN and microalbuminuria, and 49 with DN and macroalbuminuria, as well as 296 controls. Baseline characteristics, microalbuminuria prevalence, macroalbuminuria prevalence, and diabetic complications were compared between OIF quartiles. Serum OIF was examined by enzyme-linked immunosorbent assay. Other clinical parameters were measured using standard methods. Correlations between OIF and clinical parameters were assessed using Pearson correlation. Predictive value of OIF for DN was assessed using multivariate logistic regression. Receiver operator characteristic (ROC) curves were used to identify the optimal sensitivity for serum OIF.Univariate analysis showed microalbuminuria prevalence negatively correlated with OIF, 4.3% for quartile 1 (Q1) (>367.5 pg/mL), 13.7% for Q2 (320.3-367.5 pg/mL), 17.9% for Q3 (275.0-320.3 pg/mL), and 28.8% for Q4 (<275.0 pg/mL) (Ptrend < .001), as did T2DM complications. ROC analysis showed an OIF of <343.4 pg/mL was predictive of DN (C statistic 0.702). OIF <343.4 pg/mL remained predictive of microalbuminuria (odds ratio = 11.60; 95% confidence interval: 1.25-107.47) after adjusting for confounding factors.Serum OIF is an independent diagnostic marker of DN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.